In the clinical case we presented, the use of empagliflozin enabled us to achieve excellent glycemic control in our 14-year-old patient, a result that had never been reached before with metformin therapy and lifestyle intervention, highlighting its potential in managing this challenging condition
doi:10.1017/S0007114514000178 Baker, R D et al
Some women may notice stronger appetite suppression, others may experience more noticeable side effects during dose increases, and some may see weight loss occur at a slower or faster pace
Intracellular components are first engulfed in double membrane vesicles called autophagosomes, which subsequently fuse with lysosomes for digestion of their contents and recycling of their building blocks
The volunteers were randomly assigned to receive semaglutide (up to 2.4 milligrams, the highest dose currently approved for obesity treatment) or placebo over a 72-week period